Folic Acid for the Prevention of Colorectal Adenomas
Bernard F. Cole, John A. Baron, Robert S. Sandler, Robert W. Haile, Dennis J. Ahnen, Robert S. Bresalier, Gail McKeown‐Eyssen, Robert W. Summers, Richard Ira Rothstein, Carol Ann Burke, Dale C. Snover, Timothy R. Church, John I. Allen, Douglas J. Robertson, Gerald J. Beck, John H. Bond, Tim Byers, Jack S. Mandel, Leila A. Mott, Loretta H. Pearson, Elizabeth L. Barry, Judy R. Rees, Norman E. Marcon, Fred G. Saibil, Per Magne Ueland, E. Robert Greenberg, for the Polyp Prevention Study Group
JAMA · 2007 · 939 citations
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Cole, B. F., Baron, J. A., Sandler, R. S., Haile, R. W., Ahnen, D. J., Bresalier, R. S., McKeown‐Eyssen, G., Summers, R. W., Rothstein, R. I., Burke, C. A., Snover, D. C., Church, T. R., Allen, J. I., Robertson, D. J., Beck, G. J., Bond, J. H., Byers, T., Mandel, J. S., Mott, L. A., … Group, for the P. P. S. (2007). Folic acid for the prevention of colorectal adenomas. JAMA, 297(21), 2351. https://doi.org/10.1001/jama.297.21.2351
In text: (Cole et al., 2007)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
CONTEXT: Laboratory and epidemiological data suggest that folic acid may have an antineoplastic effect in the large intestine. OBJECTIVE: To assess the safety and efficacy of folic acid supplementation for preventing colorectal adenomas. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, placebo-controlled, 2-factor, phase 3, randomized clinical trial conducted at 9 clinical centers between July 6, 1994, and October 1, 2004. Participants included 1021 men and women with a recent history of colorectal adenomas and no previous invasive large intestine carcinoma. INTERVENTION: Participants were randomly assigned in a 1:1 ratio to receive 1 mg/d of folic acid (n = 516) or placebo (n = 505), and were separately randomized to receive aspirin (81 or 325 mg/d) or placebo. Follow-up consisted of 2 colonoscopic surveillance cycles (the first interval was at 3 years and the second at 3 or 5 years later). MAIN OUTCOME MEASURES: The primary outcome measure was occurrence of at least 1 colorectal adenoma. Secondary outcomes were the occurrence of advanced lesions (> or =25% villous features, high-grade dysplasia, size > or =1 cm, or invasive cancer) and adenoma multiplicity (0, 1-2, or > or =3 adenomas). RESULTS: During the first 3 years, 987 participants (96.7%) underwent colonoscopic follow-up, and the incidence of at least 1 colorectal adenoma was 44.1% for folic acid (n = 221) and 42.4% for placebo (n = 206) (unadjusted risk ratio [RR], 1.04; 95% confidence interval [CI], 0.90-1.20; P = .58). Incidence of at least 1 advanced lesion was 11.4% for folic acid (n = 57) and 8.6% for placebo (n = 42) (unadjusted RR, 1.32; 95% CI, 0.90-1.92; P = .15). A total of 607 participants (59.5%) underwent a second follow-up, and the incidence of at least 1 colorectal adenoma was 41.9% for folic acid (n = 127) and 37.2% for placebo (n = 113) (unadjusted RR, 1.13; 95% CI, 0.93-1.37; P = .23); and incidence of at least 1 advanced lesion was 11.6% for folic acid (n = 35) and 6.9% for placebo (n = 21) (unadjusted RR, 1.67; 95% CI, 1.00-2.80; P = .05). Folic acid was associated with higher risks of having 3 or more adenomas and of noncolorectal cancers. There was no significant effect modification by sex, age, smoking, alcohol use, body mass index, baseline plasma folate, or aspirin allocation. CONCLUSIONS: Folic acid at 1 mg/d does not reduce colorectal adenoma risk. Further research is needed to investigate the possibility that folic acid supplementation might increase the risk of colorectal neoplasia. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00272324.
Related papers
- Sorafenib in Advanced Hepatocellular Carcinoma2008
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer2004
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency2015
- Comprehensive molecular characterization of human colon and rectal cancer2012
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma2020
Metadata from OpenAlex (CC0). Citations are generated from the published record.